Modern approaches in the problem of epilepsy in the practice of a nurse

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The main principle of epilepsy treatment is long-term regular intake of antiepileptic drugs (PEP) to reduce the frequency of seizures or their complete reduction in the absence of clinically significant side effects. Timely detection and correction of adverse reactions is an integral part of the treatment of epilepsy.

Full Text

Restricted Access

About the authors

Sergey G. Gulian

Volgograd State Medical University of the Ministry of Health of the Russian Federation

Email: serguliyan@gmail.com

Student

Russian Federation, Volgograd

Diana E. Tsetsera

Volgograd State Medical University of the Ministry of Health of the Russian Federation

Email: diana.tsetsera@bk.ru

Student

Russian Federation, Volgograd

Vsevolod V. Skvortsov

Volgograd State Medical University of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: vskvortsov1@ya.ru
ORCID iD: 0000-0002-2164-3537

Doctor of Medicine, Professor of the Department of Internal Medicine

Russian Federation, Volgograd

Irina V. Rodionova

Volgograd State Medical University of the Ministry of Health of the Russian Federation

Email: vskvortsov1@ya.ru

Candidate of Medical Sciences, Associate Professor of the Department of Internal Medicine

Russian Federation, Volgograd

References

  1. Vera-González A. Pathophysiological Mechanisms Underlying the Etiologies of Seizures and Epilepsy. Exon Publications. 2022; 1–13.
  2. Chen J. et al. Pathogenesis of seizures and epilepsy after stroke. Acta Epileptologica. 2022; 4: 1–6.
  3. Scheffer I.E., Berkovic S., Capovilla G. et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58 (4): 512–521.
  4. Vezzani A., Fujinami R.S., White H.S. et al. Infections, inflammation and epilepsy. Acta Neuropathol. 2016; 131 (2): 211–234.
  5. Chen, J., Ye, H., Zhang, J. et al. Pathogenesis of seizures and epilepsy after stroke. Acta Epileptologica. 2022; 4 (2).
  6. Husari K.S., Dubey D. Autoimmune Epilepsy. Neurotherapeutics. 2019; 16 (3): 685–702.
  7. Toledano M., Pittock S.J. Autoimmune Epilepsy. Semin Neurol. 2015; 35 (3): 245–258.
  8. Beghi, Ettore. The epidemiology of epilepsy. Neuroepidemiology 2020; 54 (2): 185–191.
  9. Sarmast S.T., Abdullahi A.M., Jahan N. Current Classification of Seizures and Epilepsies: Scope, Limitations and Recommendations for Future Action. Cureus. 2020; 12 (9): e10549.
  10. Scheffer I.E., Berkovic S., Capovilla G. et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58 (4): 512–521. doi: 10.1111/epi.13709. Epub 2017 Mar 8.
  11. Hirtz D., Berg A., Bettis D. et al. Practice parameter: treatment of the child with a first unprovoked seizure report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2003; 60: 166–175.
  12. Hauser W.A. Should people be treated after a first seizure? Arch Neurol. 1986; 43: 1287–1288.
  13. Pohlmann-Eden B., Beghi E., Camfield C. et al. The first seizure and its management in adults and children. BMJ. 2006; 332: 339.
  14. Parkerson K.A., Pathmanathan J.S., Milligan T.A. Optimizing antiepileptic treatment. JCOM. 2009; 16 (10).
  15. St L., Erik K., Rosenfeld W.E. et al. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol. 2009; 7: 77–82.
  16. Wheless J.W. A critical evaluation of midazolam nasal spray for the treatment of patients with seizure clusters. Expert Rev Neurother 2021; 21 (11): 1195–1205.
  17. Alvarez V., Lee J.W., Drislane F.W. et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison. Epilepsia 2015; 56 (8): 1275–1285.
  18. Trinka E., Kälviäinen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure 2017; 44: 65–73.
  19. Kapur J., Elm J., Chamberlain J.M. et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. NETT and PECARN Investigators. N Engl J Med 2019; 381 (22): 2103–2113.
  20. Möddel G., Bunten S., Dobis C. et al. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. J Neurol Neurosurg Psychiatry 2009; 80 (6): 689–692.
  21. Chamberlain J.M., Kapur J., Shinnar S. et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet 2020; 395 (10231): 1217–1224.
  22. Kim H.K., Lee H., Bae E-K. et al. Cardiac effects of rapid intravenous loading of lacosamide in patients with epilepsy. Epilepsy Res 2021; 176: 106710.
  23. Amengual-Gual M., Sanchez Fernandez I., Wainwright M.S. Novel drugs and early polypharmacotherapy in status epilepticus. Seizure 2019; 68 (3): 79–88.
  24. Fujikawa D.G. Starting ketamine for neuroprotection earlier than its current use as an anesthetic/antiepileptic drug late in refractory status epilepticus. Epilepsia 2019; 60 (5): 373–380.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Russkiy Vrach Publishing House